Start an analysis for TKR
The Timken Company
Stock · NYSEProgram summary
| Field | Value | As of | Source |
|---|---|---|---|
| Current authorization | $1.0bnEST | 30-Sep-26 | 10-Q filed 04-Nov-26 |
| Remaining authorization | $949mEST | 30-Sep-26 | 10-Q filed 04-Nov-26 |
| Program expiry | 28-Feb-31 | 30-Sep-26 | 10-Q filed 04-Nov-26 |
| Repurchased last quarter | $63m | 30-Sep-26 | 10-Q filed 04-Nov-26 |
| Has used an ASR | No | — |
Remaining authorization is estimated: we derive it from reported spend, or convert a share authorization at the latest close. Check the linked filings.
Programs
| Authorized on | Authorized | Remaining | Expires | Terms |
|---|---|---|---|---|
| 13-Feb-26 | $1.0bnEST 10.0m sh | $949mEST 9.1m sh left | 28-Feb-31 | On February 13, 2026, the Company announced that its Board of Directors approved a new share repurchase plan, effective March 1, 2026, pursuant to which the Company may purchase up to ten million of its common shares, in the aggregate. This share purchase plan expires on February 28, 2031.10-Q filed 04-Nov-26 |
Open-market repurchases
- Apr ’26
- May ’26
- Jun ’26
- Jul ’26
- Aug ’26
- Sep ’26
| Month ended | Shares | Withheld & other | Avg price | ≈ Value | Source |
|---|---|---|---|---|---|
| 30-Sep-26 | 243,000 | 16,084 | $118.30 | $29m | 10-Q filed 04-Nov-26 |
| 31-Aug-26 | 160,539 | — | $127.08 | $20m | 10-Q filed 04-Nov-26 |
| 31-Jul-26 | 100,697 | 127 | $139.10 | $14m | 10-Q filed 04-Nov-26 |
| 30-Jun-26 | 105,582 | 968 | $136.65 | $14m | 10-Q filed 04-Aug-26 |